57 related articles for article (PubMed ID: 30223267)
1. A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Huang J; Gui C; Zhang L; Che F; Wang C
Cell Physiol Biochem; 2018; 49(4):1589-1599. PubMed ID: 30223267
[TBL] [Abstract][Full Text] [Related]
2. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Jaramillo S; Le Cornet L; Kratzmann M; Krisam J; Görner M; Hänel M; Röllig C; Wass M; Scholl S; Ringhoffer M; Reichart A; Steffen B; Kayser S; Mikesch JH; Schaefer-Eckart K; Schubert J; Geer T; Martin S; Kieser M; Sauer T; Kriegsmann K; Hundemer M; Serve H; Bornhäuser M; Müller-Tidow C; Schlenk RF
Trials; 2023 Sep; 24(1):591. PubMed ID: 37715270
[TBL] [Abstract][Full Text] [Related]
3. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Gao XN; Su YF; Li MY; Jing Y; Wang J; Xu L; Zhang LL; Wang A; Wang YZ; Zheng X; Li YF; Liu DH
Cancer Immunol Immunother; 2023 Aug; 72(8):2769-2782. PubMed ID: 37166484
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Martínez-Cuadrón D; Megías-Vericat JE; Gil C; Bernal T; Tormo M; Martínez-Sánchez P; Rodríguez-Medina C; Serrano J; Herrera P; Simón JAP; Sayas MJ; Bergua J; Lavilla-Rubira E; Amigo ML; Benavente C; Lorenzo JLL; Pérez-Encinas MM; Vidriales MB; Colorado M; De Rueda B; García-Boyero R; Marini S; García-Suárez J; López-Pavía M; Gómez-Roncero MI; Noriega V; López A; Labrador J; Cabello A; Sossa C; Algarra L; Stevenazzi M; Solana-Altabella A; Boluda B; Montesinos P
Haematologica; 2024 Jan; 109(1):115-128. PubMed ID: 37199127
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.
Li W; Gong X; Sun M; Zhao X; Gong B; Wei H; Mi Y; Wang J
PLoS One; 2014; 9(10):e110153. PubMed ID: 25299623
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S; Montesinos P; Schuh AC; Papayannidis C; Vyas P; Wei AH; Ommen H; Semochkin S; Kim HJ; Larson RA; Koprivnikar J; Frankfurt O; Thol F; Chromik J; Byrne J; Pigneux A; Thomas X; Salamero O; Vidriales MB; Doronin V; Döhner H; Fathi AT; Laille E; Yu X; Hasan M; Martin-Regueira P; DiNardo CD
Blood; 2023 Jan; 141(2):156-167. PubMed ID: 35714312
[TBL] [Abstract][Full Text] [Related]
7. A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Sidi Y; Dong C; Wu Y; Faller DV
Leuk Res; 2024 Mar; 138():107465. PubMed ID: 38422881
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Sanchez-Petitto G; Goloubeva OG; Masur J; Childress J; Iqbal T; An M; Muhammad S; Lawson J; Li G; Barr B; Emadi A; Law JY; Lee ST; Duong VH; Baer MR; Niyongere S
Leuk Res; 2024 Mar; 138():107456. PubMed ID: 38442593
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis.
Cai Z; Yin Y; Zhao Z; Xin C; Cai Z; Yin Y; Shen C; Yin X; Wang J; Chen Z; Zhou Y; Zhang B
Front Pharmacol; 2018; 9():872. PubMed ID: 30127746
[No Abstract] [Full Text] [Related]
10. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
van der Maas NG; Versluis J; Nasserinejad K; van Rosmalen J; Pabst T; Maertens J; Breems D; Manz M; Cloos J; Ossenkoppele GJ; Floisand Y; Gradowska P; Löwenberg B; Huls G; Postmus D; Pignatti F; Cornelissen JJ
Blood Cancer J; 2024 Mar; 14(1):56. PubMed ID: 38538587
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Ravandi F; Gojo I; Patnaik MM; Minden MD; Kantarjian H; Johnson-Levonas AO; Fancourt C; Lam R; Jones MB; Knox CD; Rose S; Patel PS; Tibes R
Leuk Res; 2016 Sep; 48():92-100. PubMed ID: 27544076
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A; Kantarjian H; Bazinet A; Kadia T; Daver N; DiNardo CD; Borthakur G; Loghavi S; Patel K; Tang G; Sasaki K; Short NJ; Yilmaz M; Issa GC; Alvarado Y; Montalban-Bravo G; Maiti A; Abbas HA; Takahashi K; Pierce S; Jabbour E; Garcia-Manero G; Ravandi F
Haematologica; 2024 May; ():. PubMed ID: 38695144
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Frontline Chemotherapy for Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Network Meta-Analysis.
Luo F; Wang JN; Liu X; Wang X; Qi SN; Li YX
J Hematol; 2023 Oct; 12(5):215-226. PubMed ID: 37936976
[TBL] [Abstract][Full Text] [Related]
14. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Pleyer L; Vaisband M; Drost M; Pfeilstöcker M; Stauder R; Heibl S; Sill H; Girschikofsky M; Stampfl-Mattersberger M; Pichler A; Hartmann B; Petzer A; Schreder M; Schmitt CA; Vallet S; Melchardt T; Zebisch A; Pichler P; Zaborsky N; Machherndl-Spandl S; Wolf D; Keil F; Hasenauer J; Larcher-Senn J; Greil R
Am J Hematol; 2023 Nov; 98(11):1685-1698. PubMed ID: 37548390
[TBL] [Abstract][Full Text] [Related]
15. Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
Le RQ; Przepiorka D; Chen H; Shen YL; Pulte ED; Norsworthy KJ; Theoret MR; De Claro RA
Blood; 2024 May; ():. PubMed ID: 38728428
[TBL] [Abstract][Full Text] [Related]
16. Optimization of individualized dynamic treatment regimes for recurrent diseases.
Huang X; Ning J; Wahed AS
Stat Med; 2014 Jun; 33(14):2363-78. PubMed ID: 24510534
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
18. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
DiNardo CD
N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30231226
[No Abstract] [Full Text] [Related]
19. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Blommestein HM; van Beurden-Tan CHY; Franken MG; Uyl-de Groot CA; Sonneveld P; Zweegman S
Haematologica; 2019 May; 104(5):1026-1035. PubMed ID: 30606791
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
Li Y; Tang T; Xiao J; Li B; Yang W; Xie S; Du Y; Huang K; Nie D
Ann Hematol; 2022 Jul; 101(7):1509-1522. PubMed ID: 35445843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
